Literature DB >> 29762168

Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults.

Pierre Duffau1,2, Alexandra Ozanne3, Fabrice Bonnet3,4, Estibaliz Lazaro1,5, Charles Cazanave6, Patrick Blanco1,7, Etienne Rivière5, Arnaud Desclaux6, Caroline Hyernard1, Noemie Gensous2, I Pellegrin3,7, L Wittkop3,8.   

Abstract

BACKGROUND: The widespread introduction of combination antiretroviral therapy (cART) has increased survival of HIV-infected patients. However, the prevalence of age-related comorbidities remains higher than that of the general population, suggesting that individuals with HIV suffer from accelerated aging. Immune activation, senescence and inflammation could play an important role in this process.
METHODS: The CIADIS (Chronic Immune Activation anD Senescence) sub-study analyzed biomarkers of activation, differentiation and senescence of T cells in a cellular-CIADIS-weighted score, whereas biomarkers of inflammation were analyzed in a soluble CIADIS-weighted score using principal component analysis. Adjusted logistic regression and Cox proportional hazard models were used to determine the association between CIADIS-weighted scores and the presence of multimorbidity, time to occurrence of the first new age-related comorbidity and time to death, over a 3-year follow-up period.
RESULTS: Of 828 patients with an undetectable viral load, a higher cellular-CIADIS-weighted score and higher TNFRI levels were independently associated with the presence of multimorbidity (OR 1.3; 95% CI 1.0-1.6; P = 0.02), but the soluble CIADIS-weighted score was not (OR = 1.1; 95% CI 0.9-1.3; P = 0.33). A higher cellular CIADIS-weighted score (hazard ratio 2.2; P < 0.01), higher levels of CD8 activation and a lower CD4/CD8 ratio were associated with a higher risk of age-related comorbidities. Only TNFRI was associated with mortality in a 3-year period.
CONCLUSION: The cellular CIADIS-weighted score was independently associated with both multimorbidity at inclusion and the risk of new age-related comorbidity during a 3- year follow-up. TNFRI was associated a higher risk for mortality.

Entities:  

Mesh:

Year:  2018        PMID: 29762168     DOI: 10.1097/QAD.0000000000001875

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

2.  Inflammation-related genes are associated with epigenetic aging in HIV.

Authors:  Erin E Sundermann; Mariam A Hussain; David J Moore; Steven Horvath; David T S Lin; Michael S Kobor; Andrew Levine
Journal:  J Neurovirol       Date:  2019-07-08       Impact factor: 2.643

3.  World AIDS Day: 40 years of an evolving pulmonary landscape.

Authors:  Kristina Crothers; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-11-10       Impact factor: 5.464

4.  Individuals With Higher CD4/CD8 Ratio Exhibit Increased Risk of Acute Respiratory Distress Syndrome and In-Hospital Mortality During Acute SARS-CoV-2 Infection.

Authors:  Ana Pascual-Dapena; Juan José Chillaron; Gemma Llauradó; Isabel Arnau-Barres; Juana Flores; Inmaculada Lopez-Montesinos; Luisa Sorlí; Juan Luis Martínez-Pérez; Silvia Gómez-Zorrilla; Juan Du; Natalia García-Giralt; Robert Güerri-Fernández
Journal:  Front Med (Lausanne)       Date:  2022-06-23

Review 5.  The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy.

Authors:  Erin M B Scholz; Angela D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2021-02-28       Impact factor: 6.875

6.  Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Authors:  Cecilia Sgadari; Paolo Monini; Antonella Tripiciano; Orietta Picconi; Anna Casabianca; Chiara Orlandi; Sonia Moretti; Vittorio Francavilla; Angela Arancio; Giovanni Paniccia; Massimo Campagna; Stefania Bellino; Marianna Meschiari; Silvia Nozza; Laura Sighinolfi; Alessandra Latini; Antonio Muscatello; Annalisa Saracino; Massimo Di Pietro; Massimo Galli; Aurelio Cafaro; Mauro Magnani; Fabrizio Ensoli; Barbara Ensoli
Journal:  Front Immunol       Date:  2019-02-13       Impact factor: 7.561

Review 7.  Dysfunctional Immunometabolism in HIV Infection: Contributing Factors and Implications for Age-Related Comorbid Diseases.

Authors:  Tiffany R Butterfield; Alan L Landay; Joshua J Anzinger
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

8.  Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging.

Authors:  Erin E Sundermann; Kristine M Erlandson; Caitlin N Pope; Anna Rubtsova; Jessica Montoya; Alison A Moore; Catia Marzolini; Kelly K O'Brien; Savita Pahwa; Brendan A I Payne; Leah H Rubin; Sharon Walmsley; Norman J Haughey; Monty Montano; Maile Y Karris; Joseph B Margolick; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-10       Impact factor: 1.723

9.  Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Emily Paolillo; Rowan Saloner; Robert K Heaton
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

10.  Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Thomas A Premeaux; Shireen Javandel; Kalei R J Hosaka; Meredith Greene; Nicholas Therrien; Isabel E Allen; Michael J Corley; Victor G Valcour; Lishomwa C Ndhlovu
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.